Navigation Links
Genyous Biomed Announces Private Placement Financing
Date:1/29/2009

Company will leverage multivalent drug development platform, expand oncology pipeline, and explore potential for other chronic diseases

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Genyous Biomed International Inc. ("Genyous") announced today that it has entered into a $36 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $12 million before March 31, 2009, $12 million before December 31, 2009 and $12 million before December 31, 2010. Genyous anticipates that these funds will cover operations for three years. "This financing will enable us to further develop our oncology pipeline," said James Dao, Chairman & CEO of Genyous. "In addition, we will be able to leverage our MFMT(TM) drug development platform and extend into other chronic diseases of interest which include BPH, COPD, pain and CNS," said Mr. Dao.

MFMT(TM) drugs, a Genyous innovation, possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases. These multivalent therapies were designed using a systems biology strategy that takes into consideration crosstalk between cells, their microenvironment and the host organism (e.g. the immune system response). The comprehensive therapeutic activity profile of MFMT(TM) drugs represents an opportunity to significantly improve outcomes. By possessing multiple therapeutic functions and working through a multiplicity of biological targets, relatively low and well-tolerated doses of therapeutic actives are sufficient to treat diseases while minimizing disruption of and restoring the body's homeostasis. This unique characteristic of MFMT(TM) drug candidates leads to less risk of toxicity, side effects and development of drug resistance.

Chronic diseases are now at the center of America's healthcare crisis. According to the U.S. Centers for Disease Control and Prevention, an estimated 133 million people (more than one in three Americans), live with at least one chronic condition and the number continues to grow rapidly. Seventy-five percent of the $2.1 trillion spent on healthcare in the U.S. goes to treating people who suffer from chronic conditions. However, the efficacy and safety of these therapies for chronic diseases has not improved significantly for the past 50 years. For example the cancer mortality rate in the U.S. has only decreased by 5 percent since 1950.

About Genyous Biomed International Inc.

Genyous Biomed International Inc., www.genyous.com, was founded in 2000 to find new solutions for treating chronic diseases. The Company has developed the novel Multifunctional Multitargeted (MFMT(TM)) drug development platform to create multivalent drugs designed to address the heterogeneous nature of chronic diseases. Our lead drug candidates are poised for clinical trials in numerous therapeutic areas including cancer, pain, CNS and pre-cancerous indications such as BPH and COPD.


'/>"/>
SOURCE Genyous Biomed International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
2. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
3. BioMed Realty Trusts Center for Life Science Boston Now 91% Leased
4. BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
5. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
7. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
8. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
9. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
10. Response Biomedical Corporation Announces Change of Executives
11. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: